570 related articles for article (PubMed ID: 26037791)
1. Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis.
Al Nofal AA; Altayar O; BenKhadra K; Qasim Agha OQ; Asi N; Nabhan M; Prokop LJ; Tebben P; Murad MH
Osteoporos Int; 2015 Jul; 26(7):1875-91. PubMed ID: 26037791
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.
Alvarez L; Guañabens N; Peris P; Vidal S; Ros I; Monegal A; Bedini JL; Deulofeu R; Pons F; Muñoz-Gomez J; Ballesta AM
Bone; 2001 Nov; 29(5):447-52. PubMed ID: 11704497
[TBL] [Abstract][Full Text] [Related]
3. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and treatment of Paget's disease of bone : A clinical practice guideline.
Muschitz C; Feichtinger X; Haschka J; Kocijan R
Wien Med Wochenschr; 2017 Feb; 167(1-2):18-24. PubMed ID: 27600563
[TBL] [Abstract][Full Text] [Related]
5. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone.
Reid IR; Davidson JS; Wattie D; Wu F; Lucas J; Gamble GD; Rutland MD; Cundy T
Bone; 2004 Jul; 35(1):224-30. PubMed ID: 15207761
[TBL] [Abstract][Full Text] [Related]
6. Biochemical assessment of Paget's disease of bone.
Shankar S; Hosking DJ
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P22-7. PubMed ID: 17229003
[TBL] [Abstract][Full Text] [Related]
7. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM
Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934
[TBL] [Abstract][Full Text] [Related]
8. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of oral risedronate therapy in Japanese patients with Paget's disease of bone.
Ohara M; Imanishi Y; Nagata Y; Ishii A; Kobayashi I; Mori K; Ito M; Miki T; Nishizawa Y; Inaba M
J Bone Miner Metab; 2015 Sep; 33(5):584-90. PubMed ID: 25319558
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone.
Reid IR; Maslowski K
Calcif Tissue Int; 2017 Jul; 101(1):43-49. PubMed ID: 28324123
[TBL] [Abstract][Full Text] [Related]
11. Quantitative evaluation of bone scintigraphy in the assessment of Paget's disease activity.
Pons F; Alvarez L; Peris P; Guañabens N; Vidal-Sicart S; Monegal A; Pavía J; Ballesta AM; Muños-Gómez J; Herranz R
Nucl Med Commun; 1999 Jun; 20(6):525-8. PubMed ID: 10451864
[TBL] [Abstract][Full Text] [Related]
12. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
[TBL] [Abstract][Full Text] [Related]
13. Two cases of monostotic Paget's disease: effects of bisphosphonate.
Hoshiro M; Harada T; Iwai H; Miyatake T; Nishimura A; Ohno Y; Aoki N
Endocr J; 2003 Aug; 50(4):385-92. PubMed ID: 14599111
[TBL] [Abstract][Full Text] [Related]
14. [Paget's disease of bone].
Holgado Pérez S; Sallés Lizarzáburu M; Olivé Marqués A
Med Clin (Barc); 2008 Oct; 131(13):509-12. PubMed ID: 19007581
[No Abstract] [Full Text] [Related]
15. [Paget's disease: case report].
Wegierska M; Ignaczak P; Zalewska J; Jeka S
Ann Acad Med Stetin; 2011; 57(3):64-9; discussion 69. PubMed ID: 23383549
[TBL] [Abstract][Full Text] [Related]
16. Symptomatic and scintigraphic improvement after intravenous pamidronate treatment of Paget's disease of bone in patients with normal serum alkaline phosphatase levels.
Ang G; Feiglin D; Moses AM
Endocr Pract; 2003; 9(4):280-3. PubMed ID: 14561571
[TBL] [Abstract][Full Text] [Related]
17. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
[TBL] [Abstract][Full Text] [Related]
18. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
Hosking D; Lyles K; Brown JP; Fraser WD; Miller P; Curiel MD; Devogelaer JP; Hooper M; Su G; Zelenakas K; Pak J; Fashola T; Saidi Y; Eriksen EF; Reid IR
J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
[TBL] [Abstract][Full Text] [Related]
19. Comparison of methods of assessing response of Paget's disease to bisphosphonate therapy.
Patel S; Coupland CA; Stone MD; Hosking DJ
Bone; 1995 Feb; 16(2):193-7. PubMed ID: 7756047
[TBL] [Abstract][Full Text] [Related]
20. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
